Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to $799.9 million.

  • Mereo BioPharma Group's Shares Outstanding (Diluted Average) rose 3.87% to $799.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $799.9 million, marking a year-over-year increase of 3.87%. This contributed to the annual value of $739.6 million for FY2024, which is 12.16% up from last year.
  • Mereo BioPharma Group's Shares Outstanding (Diluted Average) amounted to $799.9 million in Q3 2025, which was up 0.06% from $799.4 million recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma Group's Shares Outstanding (Diluted Average) peaked at $799.9 million during Q3 2025, and registered a low of $623.9 million during Q1 2023.
  • For the 3-year period, Mereo BioPharma Group's Shares Outstanding (Diluted Average) averaged around $733.2 million, with its median value being $754.9 million (2024).
  • In the last 5 years, Mereo BioPharma Group's Shares Outstanding (Diluted Average) spiked by 418.76% in 2021 and then fell by 3.10% in 2022.
  • Over the past 5 years, Mereo BioPharma Group's Shares Outstanding (Diluted Average) (Quarterly) stood at $758.8 million in 2021, then declined by 3.10% to $735.3 million in 2022, then reached $659.5 million in 2023, then climbed by 12.16% to $739.6 million in 2024, then rose by 3.87% to $799.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $799.9 million in Q3 2025, compared to $799.4 million in Q2 2025 and $784.3 million in Q1 2025.